1122 GMT - Robert F. Kennedy Jr.'s nomination as Health and Human Services secretary will likely impact vaccine makers and the Food and Drug Administration, Jefferies analysts write. Kennedy has publicly criticized childhood and mRNA-based vaccines, the analysts say. Vaccine perception in the U.S. could suffer, leading to lower demand and sales and potentially cause outbreaks if vaccinations are not consistent over the next four years, Jefferies says. Kennedy has also been vocal on overhauling the FDA, which could alter the regulatory path, resources for biotech and drug review positions as well as impacting key FDA leadership. Bavarian Nordic shares are down 16%, with Valneva down 6%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
November 15, 2024 06:22 ET (11:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。